Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 4, 2026Journal of Clinical Oncology

Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer: First results of the PEACE-2 randomized phase III trial.

View Full Paper
Ask AI
Bookmark
Share

Authors

KFKarim FizaziJCJoan CarlesSFS. Foulon

Discussion

Loading...

Member takes

Overview

PEACE-2 trial evaluates cabazitaxel's effects on outcomes in localized prostate cancer patients, suggesting limited benefits.

Key Points

  • The aim is to assess if adding cabazitaxel to standard treatment improves survival outcomes in very-high risk localized prostate cancer.
  • Randomized 2x2 factorial design trial with SOC plus combinations of cabazitaxel and pelvic radiotherapy
  • Participants included patients meeting specific high-risk criteria with no detectable metastases
  • Primary endpoint focused on clinical progression-free survival
  • Statistical analysis using Cox and logrank methods for hazard ratios
  • Cabazitaxel did not improve clinical progression-free survival (HR: 1.11; 6-year cPFS rates: 67.2% vs 71.4%)
  • Overall survival rates exceeded 85% across all treatment arms
  • Grade >2 toxicity occurred in 65% of those receiving cabazitaxel and in 47% without it

Cite This Study

Fizazi et al. (2026) studied this question.

synapsesocial.com/papers/69a7ccb2d48f933b5eed85e0https://doi.org/10.1200/jco.2026.44.7_suppl.lba307
View Full Paper
Ask AI
Bookmark
Share